Bioparox (fusafungine) spray: new contra-indications and recommendations to minimize the risk of serious allergic reactions

Information for healthcare professionals, Scientific Centre of drug and medical technology expertise after academician E. Gabrielyan on behalf of drug safety...


more ...

In addition to our letter N0401126314 dated on 30.10.2014

Dear Sir/Madam, In addition to our letter N0401126314 dated on 30.10.2014 please be informed that electronic versions of medicine’s mock-ups, leaflet...


more ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has endorsed restrictions on combining different classes of medicines that act on the renin-angiotensin system (RAS)

Angiotensin-receptor blockers (ARBs, sometimes known as sartans), angiotensin-converting enzyme inhibitors (ACE-inhibitors) and direct renin inhibitors such as aliskiren. Combination of...


more ...

The safety information regarding the use of Xeloda® (capecitabine).

FOR HEALTHCARE PROFESSIONAL F. Hoffmann-La Roche Ltd. intends to update the safety information regarding the use of Xeloda® (capecitabine). Date 16.01.2014 Subject:       ...


more ...
0123456789

Dear friends 

The main goal of The Scientific Center of Drug and Medical Technologies Expertise (SCDMTE) is the implementation of the national drug policy that provides availability of safe, effective and quality drugs in Armenia. The transparent and public work style is very important for us, therefore this website is envisaged to make the information and the feedback connection available. 

Through this website you can find out the information about the activities, structure, current projects and reforms of the SCDMTE, as well as legislation and news relevant to the drug policy. In this updated website you can find numerous new links that can give you an integral idea about our work directed on drug quality assurance, as well as its rational and safe use. 

We would be glad to get your comments regarding our website, which would help us in its further development.